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Abstract 
Background  
The 5-item Compliance Questionnaire for Rheumatology (CQR5) allows the identification 
of patients likely be high adherers (HA) to anti-rheumatic treatment (i.e. taking ≥80% of their 
medications correctly), or “low” adherers (LA). The objective of the entire study was to 
validate an Italian version of I-CQR5 in rheumatoid arthritis (RA) patients. Furthermore, a 
cross-sectional analysis was conducted to investigate what factors are associated with 
high treatment adherence.  
Methods 
RA patients (with disease duration >1 year, undergoing treatment with ≥1 self-administered 
biological disease-modifying anti-rheumatic drugs (bDMARDs) or conventional synthetic 
DMARDs (csDMARDs), willing and capable of completing the questionnaire unaided) were 
enrolled in the study. The cross-cultural adaptation into Italian and validation of I-CQR5 
followed standardized guidelines. The I-CQR5 was completed by patients on one occasion. 
Data were subjected to Partial Credit model Parametrisation (PCM) to assess the construct 
validity and reliability of I-CQR5. Patients who gave consent to retrieve their clinical data 
were included in the analysis of factors associated with high adherence to anti-rheumatic 
treatment. Factors included were demographic and social characteristics of the patients, 
and clinical and treatment information. Factors achieving a p<0.10 in univariate analysis 
were included in a multivariate regression analysis. Separate models were conducted in 
the entire cohort and in the csDMARD only- and bDMARD- treated groups.  
Results  
Among 604 RA patients, 401 were eligible for the analysis: 274 patients were included in 
the validation analysis and 328 in the cross-sectional analysis. Median age of the patients 
was 57 years (48-134), most were females (232, 82%), median disease duration was 12 
years (7-19); 64.3% (193/300) of patients was treated with bDMARDs and 54.6% (107/300) 
with csDMARD treatment; 90.3% (270/299) of the patients was in low disease activity or 
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remission.  
Issues regarding the adaptation of CQR5 were discussed and solved by an expert 
committee assessment. The I-CQR5 was well understood by patients. Factor analysis and 
PCM confirmed the construct validity, unidimensionality and internal consistency of the I-
CQR5.  
HA were found to be 35.2% (109/310) of the patients: 40.2% (79/193) in patients treated 
with bDMARDs and 22.4% (24/107) with csDMARDs only. bDMARD treatment and 
employment were found to be independently associated with high adherence: OR 2.88 
(1.36-6.1), p=0.006 and OR 2.36 (1.21-4.62), p=0.012 respectively. Older age, lower 
education level, higher prednisone daily dose, use of a csDMARD (particulary 
hydroxychloroquine and sulfasalazine) and higher patient-VAS were significantly more 
frequent in LA compared with HA but the association was not confirmed by the multivariate 
analysis. No independent predictors were found in the group of patients treated with 
csDMARDs only. Employment was also positively and significantly associated with high 
adherence considering patients treated with bDMARDs: OR 2.89 (1.3-6.44), p=0.009.  
Conclusions 
Only one third of Italian RA patients were found to be highly adherent to treatment 
according to the I-CQR5. Treatment with bDMARDs and employment status were the major 
determinants, increasing by almost 3-fold the likelihood of being adherent. Age, education 
level, PDN daily dose, and patient global assessment on a visual analogic scale, might 
contribute in explaining adherence in RA patients.  
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Background  
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterised by persistent 
synovitis, which leads to joint disruption and disability. Optimisation of treatment strategies 
and introduction of highly effective treatments, namely biological disease-modifying anti-
rheumatic drugs (bDMARDs), improved RA outcomes in the last 30 years. Conventional 
synthetic DMARDs (csDMARDs) are recommended as first line treatment due to their 
efficacy, safety profile and relatively low cost1,2,3. Addition of a bDMARD is recommended 
in patients with inadequate response to csDMARDs or poor prognostic factors2,3. 
csDMARDs can take months to exhibit noticeable therapeutic benefits and can have side-
effects that prompt patients to be less adherent4. Adherence to csDMARDs was reported 
to be poor, with proportions of adherent patients of 10-60%5,6. Despite the rapid onset of 
action, the high efficacy and the favourable safety profile of bDMARDs, adherence to this 
class of treatments is still sub-optimal7,8.  
Non-adherence to anti-rheumatic treatment is responsible for disease progression, 
unnecessary treatment escalation, increase in the number of assessments and 
hospitalisation6,9,10,11which result in increased costs and decreased quality of life12,13,14. 
Optimisation of patients’ adherence is recognised as an unmet need in RA15 and 
recommendations for disease management advocate the investigation of potential 
implications of poor treatment adherence1,3. 
Measuring adherence is complex and no standardised technique is available. The “gold 
standard” is electronic medication event monitoring (eMEMs). However, eMEMs is 
unsuitable for clinical practice, as it requires numerous resources from both the patient 
and researcher to be implemented effectively. In large scale clinical studies, self-reported 
questionnaires are the most common methods of assessing medication adherence and 
also explore causes of poor adherence. Of the self-reported measures that have been 
developed to monitor medication adherence, most have limited sensitivity and have not 
been specifically developed for rheumatic diseases16. The Compliance-Questionnaire-
Rheumatology (CQR) is a 19-item questionnaire developed in 1999 in the Netherlands. 
CQR predicts the potential for non-adherence in rheumatology patients17. However, CQR 
can be considered lengthy at 19 items for use in a clinical setting. A study by Hughes et 
 4 
al., tested the factor structure of the CQR and reduced the number of items to 518. CQR5 
increases the clinical utility by diminishing the patient burden.  
Only a few reports on adherence measured the 5-item CQR (CQR5) are available in RA to 
date19,20 and no report on treatment adherence, assessed by the means of a validated 
questionnaire, is available for Italian patients. The objective of this study was to validate 
an Italian version of the CQR5 (I-CQR5) in RA patients. A cross-sectional analysis was then 
conducted to investigate what factors might be associated with high adherence in patients 
treated with csDMARDs and bDMARDs.  
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Methods  
Design  
The study was conducted in two phases. The first phase comprised the cross-cultural 
adaptation of the CQR5 into Italian and validation of the adapted tool, I-CQR5, in RA. The 
adaptation followed standardized guidelines for cross-cultural adaptation of patient-
reported outcome measures21. The validation was conducted using a cross-sectional 
survey in a cohort of RA patients who completed adapted version of the CQR5 (I-CQR5) 
on one occasion. Data were subjected to Rasch analysis to assess the construct validity 
and reliability of the translated tool.  
The second phase investigated what factors are associated with high adherence to anti-
rheumatic treatment, measured with the I-CQR5. Factors included demographic and social 
characteristics of the patients and clinical and treatment information. 
 
Patients  
Patients were recruited from the outpatient clinic of Padova University hospital. The 
inclusion criteria were: (1) diagnosis of RA according to the American College of 
Rheumatology 1987 classification criteria22; (2) disease duration >1 year; (3) aged 18 years 
or above; (4) undergoing treatment with at least one self-administered csDMARD or 
bDMARD (either oral, subcutaneous or intramuscular administration). Inability to complete 
the questionnaire (i.e., patients with cognitive impairment or lack of proficiency in the Italian 
language) was an exclusion criteria.  
All participants provided written informed consent before inclusion in the study. For the 
purposes of the analysis of factors associated with adherence, an additional consent was 
asked to the patients, in order to retrieve their clinical data from the local database. The 
study was carried out in accordance with the ethical standards of the Declaration of 
Helsinki (1983) and was approved by the Ethics Committee for the clinical trials of the 
province of Padova.  
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Measures  
CQR5 is a 5-item, self-administered questionnaire that derives from the CQR. The original 
CQR has 19 items, and identifies patients as “low” adherers, i.e. taking <80% of their 
medication correctly17,23. The statements of the CQR were identified through focus groups 
and clinician’s expert opinion of the likely barriers to medication taking. The four point Likert 
answering scale ranges from: “definitely don’t agree” (scored 1) to “definitely agree” (scored 
4), with lower scores indicating lower levels of adherence. The CQR was validated against 
eMEMs and was found to correctly identify 62% of LA23.  
The CQR5 version was developed after factor analysis of the CQR18. The number of items 
was reduced to 5, whilst retaining robust explanation of non-adherence to anti-rheumatic 
treatment. A structure matrix was developed, which identifies the optimal linear 
combination of the CQR5 questions to maximise its discriminant ability. Fisher’s 
classification function coefficients resulted in the following equations:  
D0 = -27.611 + (4.407*Q2) + (0.939*Q3) + (6.101*Q5) + (2.366*Q6) + (2.531*Q17) 
D1 = -33.304 + (2.801*Q2) + (5.008*Q3) + (6.471*Q5) + (1.215*Q6) + (3.252*Q17) 
Given the two parameters D0 and D1, if D0 is greater than D1 then the respondent should 
be classified as likely to be a “low” adherer (LA), i.e. likely to take <80% of the medication 
correctly. Conversely, if D1 is greater than D0 then the respondent should be classified as 
likely to be highly adherent (high adherer, HA), i.e. likely to take ≥80% of the medication 
correctly.  
The CQR5 and explains 50.3% of the variance in adherence. It has good internal 
consistency and fit to the data which can detect 69% of LA to anti-rheumatic treatment 
among RA patients18. Together with the CQR5 publication, a spreadsheet was provided. 
The spreadsheet allows the computation of the CQR5 result by inserting the score of each 
answer.  
 
Cross-cultural adaptation of CQR5  
The original (English) CQR5 was translated into Italian using the cross-cultural adaptation 
process described by Beaton et al.21. The process comprises five stages: forward 
translation, synthesis of the translations, back- translation, expert committee assessment 
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and field-testing.  
The forward translation stage from English into Italian was carried out by two independent 
professional translators whose mother tongue was Italian. Each translator provided a 
written report of the translation (T1 and T2), highlighting difficult phrases or uncertainties 
along with the rationale for their word choices. A synthesis of the two translation was 
produced by the two translators together with a third unbiased person who mediated the 
discussion of translation differences arising from T1 and T2. One common translation (T12) 
was obtained together with a report documenting the process and how issues were 
resolved. Back-translation was undertaken by two translators whose mother tongue was 
English and blinded to the original versions. They worked from the T12 version of the 
questionnaire, producing English translations (BT1 and BT2).  
The expert committee included a methodologist, 3 health professionals (2 doctors, 1 nurse), 
all the translators, the moderator of the translations and a member of the CQR5 developing 
group. The expert committee reviewed all translated versions (T1, T2, T12, BT1, BT2), 
discussing discrepancies raised in previous stages, and a consensus was reached on all 
items. A provisional version of the I-CQR5 was then administered for field-testing to 30 RA 
patients. Patients completed the I-CQR5 unaided. Afterwards they were interviewed to 
probe what they thought was meant by each questionnaire item. Both the meaning of the 
items and responses were explored.  
 
Validation of I-CQR5 
The final version of the I-CQR5 was completed by a consecutive sample of patients fulfilling 
the inclusion criteria. The questionnaires were anonymous but contained self-reported data 
(gender, age, social status, education level and disease duration). The original CQR5 
showed to fit the Rasch model or Partial Credit Model parametrisation (PCM)24. Then, PCM 
was used to test whether the I-CQR5 had retained its psychometric properties following 
the adaptation process. A Martin-Loef Likelihood ratio test was performed in order to 
assess the scale invariance for gender, age, education, social status and disease duration.  
 
Cross-sectional analysis: factors associated with high adherence  
HA and LA were defined according to I-CQR5. Patients’ and clinical information was 
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collected from the local database. A code allowed the association of the questionnaire 
result with patients’ information by a blinded investigator. Only patients who provided 
consent to retrieve their clinical data were included in this analysis.  
Data collected were: gender, age, social status, education level, employment, smoking 
habits (reported by the patients), BMI, distance from the outpatient clinic, number of 
rheumatologic assessments per year, positive rheumatoid factor (RF) and/or anti-
citrullinated peptides antibodies (ACPA), disease duration, concomitant fibromyalgia, 
conventional and bDMARD treatment, route and frequency of administration, treatment 
duration (≤ or > 24 months), combination treatment (≥2 synthetic and/or bDMARDs), 
previous bDMARD failures, mean prednisone (PDN) daily dose, non-steroideal 
antinflammatory drugs (NSAIDs) use, painkillers use, concomitant chronic treatments, 28-
joint disease activity score (DAS28), Health Assessment Questionnaire (HAQ), patients’ and 
physicians’ global health measured on a visual analogic scale (patient- and physician-VAS) 
and self-reported disease flares in the three months before the assessment25. Clinical 
information was referred to the most recent assessment of the patient.  
Considered csDMARDs were: methotrexate (MTX) (10– 25 mg weekly), leflunomide (LFN) 
(20 mg daily or every 2 days), or other, i.e. hydroxychloroquine (HCQ) 200-400 mg/day or 
sulfasalazine (SSZ) 2-3g /day. Considered bDMARDs were: abatacept (ABA), adalimumab 
(ADA), anakinra (AKN), certolizumab pegol (CZP), etanercept (ETA), golimumab (GLM) and 
tocilizumab (TCZ). Patients could receive either full-dose or low-dose bDMARD. In our 
clinical practice, patients who maintain remission for at least 6 months on a full-dose 
bDMARD undergo dose reduction and continue on low-dose until remission is maintained. 
Low-dose treatments were ABA 125 mg or TCZ 162 mg or ETA 50 mg every ≥10 days, 
ADA 40 mg or CZP 200 mg every ≥3 weeks; AKN 100 mg every ≥2 days, ETA 25 mg every 
≥1 week, GLM 50 mg every ≥45 days. PDN was used at a dose of ≤7.5 mg daily.  
 
Statistical analysis  
Data are presented in all patients and in HA and in LA. Continuous variables had a non-
normal distribution and were compared using Mann-Whitney test or Wilcoxon-Kruskal-
Wallis test. Qualitative variables were compared using Pearson’s Chi-square test or 
Fisher’s exact test. Data were reported as medians and interquartile range (IQR) for 
continuous variables, and absolute numbers and percentages, for qualitative variables.  
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Rasch model (Partial Credit Model parametrisation) 
PCM is based on the assumption of unidimensionality. A factor analysis was conducted in 
order to identify the number of latent dimensions, useful to explain the questionnaire 
response variability. The Chi-square statistic and p-value in factor analysis were computed 
to test the hypothesis that the model, with the identified number of latent dimensions, 
perfectly fitted the data with a minimal loss of information. The variables with the greater 
percentage of explained variance in the first two latent factors were included as subset 
item in the Martin-Loef test to assess the assumption of unidimensionality in PCM. PCM 
was estimated, and the item-fit statistics was reported in order to assess deviations from 
the PCM assumption for each item of the scale. Internal Consistency was analysed, 
including the Patient Separation Index Measure. Computations were performed using R 
3.3.326 with rms27 and eRm28 packages. 
Regression analysis  
Multivariate analysis was run to assess the potential of demographic and clinical variables 
(independent variables) to affect treatment adherence (dependent variable). Due to the high 
number of variables significantly associated with adherence in the univariate analysis, 
variables included in the multivariate analysis were all those with a p <0.10. Collinearity was 
assessed by the variance inflation factor (VIF), adopting a cut off of VIF = 2 as an exclusion 
criterion. A logistic regression model was used, with a backward elimination approach. The 
results of multivariate logistic regression analysis are presented as the odds ratio (OR) with 
the corresponding 95 % confidence interval (CI). Analyses were performed using SPSS 
version 24.0.  
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Results  
Patients  
Among 604 consecutive Italian RA patients, 36 were excluded because of lack of 
proficiency in the Italian language, 52 because of cognitive impairment or inability to 
complete the questionnaire unaided, and 115 were not willing to complete the 
questionnaire. Four hundred one patients fulfilled the enrolment criteria (Fig.1). Thirty 
patients were included in the cross-cultural adaptation phase, 274 in the cross-cultural 
validation phase. Of these, 231 gave consent to the association of the questionnaire result 
and their clinical information, together with 97 additional patients and were included in the 
cross-sectional analysis. Among the collected questionnaires, 24 were not completed or 
partially completed and could not be used for the purposes of this study (6 in the validation 
phase and 18 in the cross-sectional analysis). Demographic and clinical characteristics of 
the patients are described afterwards.  
 
Cross-cultural adaptation of CQR5  
Issues regarding translation included: multiple meanings of certain concepts, type of 
language style and idiomatic expressions. These were solved in the expert committee 
assessment. In the field-testing, the I-CQR5 provisional version was well understood by 
patients and no changes in the treatment domain were needed. A summary of issues arising 
from the translations and the agreements for each is presented in Table 1. The final 
questionnaire is reported in Figure 2. The expert committee deemed that the aim of 
proposing an accurate Italian version of the CQR5 was achieved.  
 
Validation of I-CQR5 
Data used for the validation phase and the patients’ information are reported in Table 2. 
Some of the self-reported information on the patients were missing and in 6 cases some of 
the answers to the questionnaire were missing and could not be used for the PCM.  
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Factor analysis 
Assessment of the response structure in the 5 items, revealed ordered thresholds in most 
items, indicating that the 4-point category response structure was working as expected. 
Test of the hypothesis showed that 2 factors were sufficient to explain the overall variability. 
The Chi-square statistic was 0.46, p=0.5 (Table 3). 
Rasch model (Partial Credit model Parametrisation) 
PCM was estimated including responses with at least one valid response per item (268 
responses). Item-fit statistics showed an overall agreement of items with proposed 
parametrisation, as the Infit statistics were comprised between 0.6-1.4 (excluding item 
no.5), according to Wright & Linacre (1994) for Likert scales. The Chi-square test showed 
agreement with PCM parametrisation by item (excluding the first item). Martin-Loef 
likelihood ratio test confirmed the unidimensionality of scales (Chi-square 65.8, degrees of 
freedom (df) 53, p=0.11). The Separation Reliability Index proved the internal consistency 
of the scale (Patient Separation Index 0.91) (Table 4). Martin-Loef Likelihood ratio test was 
used to assess the scale invariance for gender, age, education level and social status. The 
scale was invariant to age (Chi-square = 40.56, df= 28, p= 0.059), education level (Chi-
square = 49.95, df= 42, p= 0.187), social status (Chi-square = 10.46, df= 15, p= 0.79) and 
disease duration (Chi-square = 13.63, df= 36, p= 0.220); while the Martin-Loef test was 
significant for gender (Chi-square = 25.39, df= 14, p= 0.031). 
 
Cross-sectional analysis: factors associated with high adherence  
Among 328 patients included in the cross-sectional analysis, 18 had an incomplete 
questionnaire and had to be excluded. Most unanswered item was item no. 2 in 12 (66.7%) 
cases. Items no. 1 and 5 were unanswered in 9 cases (50%) each, items no. 3 and 4 in 3 
(16.7%) cases each. In 3/18 cases no item had been completed.  
Characteristics of the patients are detailed in Table 5. Median age of the patients was 57 
years (48-134) and most of them were females (232, 82%) (Table 5). Patients had a disease 
duration of 12 years (7-19), the duration of the current treatment was 7 years (3.3-10.1) with 
79.5% (178) of patients with a duration of ≥ 24 months. Most of the patients was treated 
with bDMARDs (193, 64.3%) and half of them with csDMARD treatment (165, 54.5%). Mean 
PDN daily dose was 1 mg (0-5). Almost two thirds of the patients used NSAIDs (185, 65.6%) 
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and one third used painkillers (76, 28.6%) either as chronic or as-needed treatment. Half of 
the patients (156, 53.1%) was undergoing a concomitant chronic treatment. Ninety per cent 
of the patients was in LDA or in remission (270, 90.3% and 173, 57.9% respectively). Details 
of the csDMARD and bDMARD treatment are reported in Table 6.  
 
Thirty-five per cent of the patients (109/310, 35.2%) resulted to be HA to the anti-rheumatic 
treatment according to the I-CQR5 result (Table 5). HA were significantly younger 
compared to LA: 54 (46-64.8) vs 59 years (49-66), p =0.011; and were more frequently 
employed 58, 62.4% vs 69, 35.4%, p<0.001. Education level was reported both according 
to each education level and as a qualitative variable. Low adherence to treatment was 
associated with primary/middle school education which was observed in 70% of LA 
compared with 30% of HA, p=0.016. A significant larger proportion of patients in treatment 
with a bDMARD was observed among HA compared LA: 76.7% (79) vs 57.9% (114) 
respectively, p=0.001. The use of a csDMARD was associated with low adherence to 
treatment: 44, 40.7% of HA vs 121, 62.1% of LA were using a csDMARD, p<0.001. 
Particularly, MTX and HCQ/SSZ were significantly associated with low adherence. HA 
assumed less PDN compared with LA: median daily dose was 1 (0-2.5) and 1.5 mg (0-5) 
respectively (p=0.011). Patient–VAS was lower in HA compared with LA: 20 (6-54) vs 40 
(20-56.3), p=0.003. Distance from the outpatient clinic was higher among HA: 30 (20-50) vs 
25 km (9-45) in LA, p=0.037. LA were more frequently females, had a positive RF and/or 
ACPA and a higher DAS28 compared with HA but the difference was not significant (Table 
5). Moreover, the rate of HA among 114 patients taking MTX (28.1%) and 26 taking LFN 
(23.1%) was not significantly different (p=0.605). No significant difference in adherence was 
observed between different administration routes of MTX either: 35.1% (13/37) HA in oral 
MTX and 25% (18/72) in subcutaneous/intramuscular MTX (p=0.265).  
 
The factors associated with high adherence to anti-rheumatic treatment were tested by 
multivariate analysis. Covariates were selected according to univariate analysis. Values 
achieving a p <0.10 in univariate analysis, were included in the logistic regression model: 
gender, age, BMI, employment, primary/middle school education, bDMARD treatment, 
csDMARD treatment, PDN daily dose, DAS28, patient-VAS and distance from the 
outpatient clinic. Age was excluded from the multivariate analysis because it was found to 
be collinear with employment (VIF=2.05 and 1.67 respectively). Age in employed patients 
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was significantly lower compared with unemployed: 50 (39-57) and 67 years (59-71), 
p<0.001. The final regression model is reported in Table 7. Employment and bDMARD 
treatment were found to be independently associated with high adherence to treatment. 
Treatment with a bDMARD increased by almost 3-fold the likelihood of being HA: OR 2.88 
(1.36-6.1), p=0.006. Likewise, employment was positively associated with high adherence 
with an OR of 2.36 (1.21-4.62), p=0.012 (Table 7).  
Rate of high adherence in the bDMARD group was 40.9% (79/193) while it was 22.4% 
(24/107) in patients treated with csDMARDs only (p=0.001). Significant differences were 
observed between characteristics of patients treated with bDMARDs and those treated 
only with csDMARDs (Table 6). Patients on bDMARDs were significantly younger, they were 
more often employed and had a higher education level compared with those treated with 
csDMARDs only. Patients in the bDMARD group compared to the csDMARD group had a 
longer disease and treatment duration; a higher HAQ; they took higher daily doses of PDN 
and less often took chronic medication other than the anti-rheumatic treatment. Lastly, 
patients treated with bDMARDs were usually undergoing a higher number of rheumatic 
assessments per year and were more distant from the rheumatology clinic.  
Factors significantly associated with high adherence in patients treated with csDMARDs 
only were: employment (14, 60.9% of HA vs 8, 33.7% of LA, p=0.019), a lower patient-VAS 
(10, 0-35 in HA vs 30, 10-50 in LA, p=0.03), and a higher distance from the clinic (22.5, 15-
56.5 in HA vs 15, 3-30 in LA, p=0.044) (Table 6). Factors positively associated with high 
adherence in the bDMARD group were employment (41, 64.1% in HA vs 40, 37% in LA, 
p=0.001) and higher education level (49, 62.8% vs 48, 46.2%, p=0.026). Factors negatively 
associated with high adherence were: female gender (52, 65.8% in HA vs 90, 80.4% in LA, 
p=0.024), and a higher patient-VAS (30, 10-50 in HA vs 45, 28-69 in LA, p=0.03). Patients 
receiving low-dose bDMARD were more likely to be HA, but the difference was not 
significant (29, 49.4% vs 43, 37.7%, p=0.091) (Table 6).  
Separate multivariate analysis was run to assess factors associated with high adherence in 
each group (synthetic and bDMARDs). Covariates included were those achieving a p value 
<0.10 in univariate analysis.  
In the model for patients treated with csDMARDs only, covariates were: age, employment, 
patient-VAS and distance from the clinic. Age was collinear with employment (VIF=2.221 
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and 2.038, respectively) and was excluded from the model. The logistic regression analysis 
did not find a significant model explaining factors associated with adherence in patients 
treated with csDMARDs only (Table 8).  
Covariates included in the model for patients treated with bDMARDs were: gender, 
employment, education, positive RF and/or ACPA, low-dose bDMARD, treatment with 
HCQ/SSZ and patient-VAS. No variable was excluded because of collinearity. The final 
model included 3 variables. Only employment was positively and significantly associated 
with high adherence: OR 2.89 (1.3-6.44), p=0.009 (Table 8).  
 
  
 15 
Discussion  
This is the first study evaluating adherence in RA patients by the means of I-CQR5, a 
validated Italian version of the CQR5 questionnaire. Only 35.2% of RA patients were found 
to be highly adherent to treatment. Treatment with bDMARDs and employment were the 
major factors associated with treatment adherence, increasing by almost 3-fold the 
likelihood of being highly adherent. Older age, lower education level, higher PDN daily dose, 
use of a csDMARD (particulary HCQ and SSZ) and higher patient-VAS (i.e. worse global 
health) were significantly associated with poor adherence but the association was not 
confirmed by multivariate analysis. No independent predictors were found in the group of 
patients treated with csDMARDs only, while employment was positively associated with 
high adherence in patients treated with bDMARDs.  
 
A direct comparison between adherence rate in this study and in other reports is difficult 
to perform because of the different methods used to assess adherence. None the less, the 
rate of HA in our analysis was lower compared to previous studies. In surveys including 
bDMARDs, high adherence was reported to be around 50-90% 7,8,29, although reports of 
adherence as low as 11% have been also described30. Adherence rates measured with 
CQR report high adherence in 20-90% of patients, but most of them describe rates around 
65-90% of HA31,32,33,34,35. Studies using CQR5 are only a few and do not describe rated of 
HA in a comparable cohort of RA patients19,20.  
The 19-item CQR showed good agreement with other patient-reported outcomes, but a 
rather low agreement with other study-specific questionnaires on adherence. Some studies 
reported that CQR identifies approximately double the rate of LA compared to other 
questionnaires36. It has to be taken into account that CQR5 allows only a discrete 
distinction of adherence in two categories (taking correctly ≥ or < 80% of prescribed 
medications). Other questionnaires, like CQR, allow to score adherence on a scale with 
different levels of adherence entailing lower overall rates of poor adherence.  
Compared to other questionnaires, CQR and CQR5 address to a wider burden of treatment 
adherence. Only one question on skipping of medications is included in CQR5 (item no.2). 
Medication Adherence Scale (MARS) and Morisky adherence questionnaire, which have 
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been also used in RA, have a number of questions that specifically investigate the correct 
intake of medication. CQR and CQR5 explore a general attitude of the patient toward the 
anti-rheumatic treatment and toward their rheumatologists and physicians. It has been 
shown that CQR5 results are strongly associated with the Beliefs on Medications 
Questionnaire (BMQ)37, further supporting the evidence that CQR5 reflects patients’ opinion 
on the treatment and on the global rheumatologic care rather than the correct medication 
administration.  
 
In our cohort, rate of HA in patients treated only with csDMARDs is low, which has to be 
ascribed mainly to HCQ and SSZ. These two DMARDs accounted for almost one third of 
csDMARDs in the study. HCQ and SSZ are known to be subjected to low adherence38. The 
reason of poor adherence might be due to the number of tablet assumed per day (varying 
between 1 and 6) and a minor effectiveness compared to MTX and LFN6.  
A lower rate of high adherence was observed in patients treated with MTX compared to 
those who did not take MTX. This difference was no longer present when the csDMARD-
only- and the bDMARD-treated groups were considered separately. Treatment with MTX, 
particularly association with MTX, has been described as undesirable by patients39. MTX 
has some adverse effect which constitute the main reason of poor adherence and can be 
under-recognised by the physician8,40,41. 
Numerous reports of patients’ preference for monotherapy are available8,39,42,43. In our study, 
combination of bDMARD with MTX or LFN did not affect the rate of high adherence. Among 
patients who completed the questionnaire, only one third was undergoing a combination 
treatment of a bDMARD with a csDMARD. The study sample did not adequately represent 
the entire RA population in our outpatient clinic. Recent analyses in our cohort found rates 
of combination treatment around 50-65%25,44.  
The long treatment duration (median 7 years) might explain the low rate of combination 
treatment. Adherence to anti-rheumatic treatments has been described to reduce over 
time9,45. Patients with long-standing treatments are prone to self-management of treatment 
because of tolerability issues or perception of a mild disease activity when level of pain is 
low9,46. Patients with current long-standing combination treatment might be those who well 
tolerated this treatment strategy and maintained it.  
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Furthermore, most of the patients included in the study had an adequate disease control 
(90% in low disease activity and 60% in remission). Self-discontinuation of the anti-
rheumatic treatments has been reported in patients with low levels of pain, as they might 
feel that treatment is unnecessary46. Although we found no association with RA measures, 
patients with very low disease activity might have decreased and discontinued treatment 
on purpose.  
Preference and high adherence of patients for bDMARDs has been already described6,30,47. 
Patients prefer the treatment with bDMARDs as it usually has a faster and greater 
effectiveness, but also because bDMARDs are innovative and costly6,30. Patients are in fact 
informed about of newly introduced medications and of the the differences in costs 
between csDMARds and bsDMARDs. This awareness might foster the feeling of a 
privileged health care with bDMARDs and the covet to rightful access to bDMARDs30.  
No association with disease activity measures was found except for patient-VAS in this 
study. A trend toward low adherence was found in patients with high HAQ and DAS28, 
positive RF and/or ACPA and high daily dose of PDN in univariate analysis. These variables 
are usually related with severe disease. That being so, the fact that patients with these 
characteristics were more frequently treated with bDMARDs may have reduced the 
capability of the study to show differential adherence according to disease activity.  
In most studies no significant association was found between employment and 
adherence13,29,35,48,49. In our cohort employed patients were younger and had a higher 
educational level, and both factors affected positively adherence. Nevertheless, 
employment was independently associated with high adherence. Concerns about reduced 
work ability and unemployment bother considerably RA patients50,51. Full functionality is 
essential to ensure working productivity, thereby encouraging a compliant behaviour in 
employed patients.  
In this study, a number of potential factors associated to adherence was explored and 
several associations emerged in the univariate analysis. Previous large reports analysing 
factors that drive treatment adherence have found a few and often divergent associations, 
especially regarding demographical and social variables7,29,35. The majority of these studies 
was conducted through multicentre, nation-wide surveys. A possible explanation of the 
relatively high number of association we found, is that the study was performed in one 
centre which collects mainly patients from the same geographical region. On one side, the 
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analysis conducted in a restricted area limits the generalisability of the results to the entire 
Italian RA population. On the other side, being limited to one area, potential confounders 
such as social and cultural variability, as well as accessibility to treatments, were reduced.  
 
The study has some limits. Firstly, the use of a questionnaire to measure adherence might 
be subjected to some bias as questionnaires are prone to prejudiced results from socially 
desirable answering52. The adoption of anonymous questionnaires, correct item 
construction and validation –which was properly undertaken in this study- can overcome 
these issues.  
Secondly, the sample was not representative of the entire RA population in our centre. 
About 10% of RA patients had to be excluded because of inability to complete the 
questionnaire. The patients not included in the analysis patients were mostly elderly or 
foreigners. These groups of patients are also subjected to incorrect administration of 
treatment because of cognitive impairment or linguistic and cultural barriers. The rate of 
adherence in these patients should also be assessed, being a considerable proportion of 
patients.  
 
The study provided the first large cross sectional analysis of treatment adherence assessed 
with the validated I-CQR5 questionnaire in a monocentric cohort in Italy. The I-CQR5 was 
well understood and appreciated by patients. Furthermore, the I-CQR5 was easy to 
administer and very little time-consuming for the physician. The study reports a higher 
adherence to bDMARDs compared to csDMARDs which is consistent with previous 
reports, but a rather poor overall adherence to anti-rheumatic drugs. CQR5 and I-CQR5 
address a broader patient perspective on the anti-rheumatic treatment. They might identify 
as LA not only patients who skip or discontinue the medication, but also patients with 
certain concerns and misbeliefs on medical treatment. Further studies are needed to 
evaluate actual administration and medical possession in LA and HA identified by I-CQR5. 
The potential effect of adherence, measured with I-CQR5, on treatment survival and 
disease outcomes on the long-term follow-up should also be determined.  
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Table 1. Original CQR5 version, back-translations, issues and agreement on the I-CQR5 discussed by the expert committee for each item of 
the questionnaire.  
 
Original Back-translation 1 (BT1) 
Back-translation 2 
(BT2) Issues Agreement 
 
Title 
 
    
5 Item version of the 
Compliance 
Questionnaire for 
Rheumatology  
Questionnaire on 
Rheumatology 
Compliance composed 
of 5 questions. 
5-Item Questionnaire on 
Compliance in 
Rheumatology  
Uncertainty on the use of the term “compliance” was discussed. The 
Italian term “aderenza” seemed more appropriate to describe patients’ 
agreement on the treatment they have been prescribed. Nevertheless, 
“adherence” meand “adherence”. “Compliance” allows to specifically 
refer to the original questionnaire version.  
Questionario sulla 
Compliance in 
Reumatologia a 5 
domande. 
Acronym 
 
    
CQR5 CQR5 CQR5 The acronym I-CQR5 specifically refers to the original questionnaire 
version. 
I-CQR5 
 
 
Introduction 
 
    
On the next pages you 
will find a number of 
statements made by 
patients with a rheumatic 
disease. Please indicate 
for each statement how 
far you agree, by placing 
a circle around the 
number that reflects your 
opinion best.   
 
 
Below there are some 
statements made by 
patients affected by 
rheumatic diseases. 
Indicate to what extent 
you agree with each 
statement by circling the 
number that best 
reflects your opinion. 
Below there are 
statements made by 
patients with rheumatic 
diseases. Please, circle 
the number that best 
reflects your opinion.  
Considering the mean age of patients with rheumatoid arthritis, it was 
deemed more pragmatically suitable to adopt a more formal style.  
The first singular person statements were turned into the formal pronoun 
accordingly. 
Different options for the translation of "to find", "statements", "how far" 
are available in the Italian language. The choice has been made in order 
to maintain a more formal style.  
Di seguito sono 
riportate delle 
affermazioni di pazienti 
affetti da una malattia 
reumatica. Indichi 
quanto è d’accordo con 
ciascuna affermazione 
cerchiando il numero 
che riflette 
maggiormente la Sua 
opinione.  
Item no. 1     
 
I take my anti-rheumatic 
medicines because I then 
have fewer problems 
I take my antirheumatic 
medication so that I’ll 
have less symptoms. 
I take the antirheumatic 
medication so I can feel 
better. 
Uncertainty on the translation of "to take" was discussed. “Assumere” 
was a more suitable term according to the formal style of the 
questionnaire, but it usually refers to oral medications. “Prendere” is less 
formal but it was deemed more suitable as it has a broader meaning 
referring also to subcutaneous and intramuscular treatments..  
Prendo i farmaci 
antireumatici perché in 
questo modo ho meno 
disturbi. 
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Item no. 2 
 
    
I definitely don’t dare to 
miss my anti-rheumatic 
medications  
I don’t ever allow myself 
to skip taking my 
medication.  
I never skip my 
medication. 
None. Non mi permetto mai di 
saltare la 
somministrazione dei 
farmaci antireumatici.  
 
Item no. 3 
 
    
My medicines are always 
stored in the same place 
and that’s why I don’t 
forget them  
I always put my 
medication in the same 
place so that I don’t 
forget to take it. 
I put my medication in the 
same place so I don’t 
forget to take it. 
Uncertainty on the translation of "to store" was discussed.  Metto sempre le 
medicine nello stesso 
posto per non 
dimenticare di 
prenderle.  
 
Item no. 4 
 
    
I take my medicines 
because I have complete 
confidence in my 
rheumatologist 
I take my prescribed 
medication because I 
have complete faith in 
my rheumatologist. 
I take the medication my 
rheumatologist prescribed 
because I trust him/her 
completely. 
Uncertainty on the translation of "to take" was discussed (see item no.2). Prendo i farmaci 
prescritti perché ho 
completa fiducia nel mio 
reumatologo. 
Item no. 5 
 
    
What the doctor tells me, 
I hang on to  
I always follow my 
doctor’s instructions. 
I always follow my 
doctor’s 
recommendations. 
Uncertainty has arisen on the type of doctor the item refers to, either the 
general practitioner or the rheumatologist. Committee deemed that the 
original distinction between the rheumatologist (in Item no. 4) and the 
doctor (Item no. 5) should be kept to ensure the same consistency of the 
original questionnaire.  
The term “medico” was chosen instead of “dottore”, as “medico” has 
usually a broader meaning compared with "dottore”.  
Seguo sempre le 
indicazioni del mio 
medico.  
Answers 
 
    
Don’t agree at all 
Don’t agree 
Agree 
Agree very much 
Don’t agree at all 
Don’t agree 
Agree 
Agree very much 
Don’t agree at all 
Don’t agree 
Agree 
Agree very much 
Translation was chosen according to the most common Likert-scale 
answers adopted in the main Italian questionnaires, e.g. those used by 
the National Italian Institute of Statistics (ISTAT). 
Completamente in 
disaccordo 
In disaccordo 
D’accordo  
Completamente 
d’accordo 
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Table 2. Characteristics of the patients and questionnaires used for the cross-cultural 
validation. 
 
 All HA LA p value 
No. 268 93 175  
Females, n (%) 201 (77) 64 (69) 137 (81) 0.025 
Age, years (IQR) 57 (48-67) 55.5 (48-64.5) 58.0 (49-67.5) 0.177 
Education level    0.121 
Primary school, n (%)  29 (12) 9 (10) 9 (10)  
Middle school, n (%) 97 (39) 27 (30) 27 (30)  
Secondary school, n 
(%) 87 (35) 36 (40) 36 (40) 
 
University, n (%) 37 (15) 17 (19) 17 (19)  
Social status    0.76 
Living with parents 
and family, n (%) 13 (6) 3 (5) 10 (7) 
 
Living alone, n (%) 30 (14) 8 (12) 22 (14)  
Living with partner 
and family, n (%) 159 (73) 47 (73) 112 (73) 
 
Other, n (%) 15 (7) 6 (9) 9 (6)  
Disease duration, 
years, median (IQR) 13.5(8.8-19.3) 13 (8-20) 12.0 (6.8-20) 
0.365 
     
Item no. 1     
Answer no. 1, n (%) 112 (42) 28 (30) 84 (48) <0.001 
Answer no. 2, n (%) 83 (31) 18 (19) 65 (37)  
Answer no. 3, n (%) 32 (12) 18 (19) 14 (8)  
Answer no. 4, n (%) 41 (15) 29 (31) 12 (7)  
Item no. 2     
Answer no. 1, n (%) 113 (42) 0 (0) 113 (65) <0.001 
Answer no. 2, n (%) 79 (29) 24 (26) 55 (31)  
Answer no. 3, n (%) 39 (15) 32 (34) 7 (4)  
Answer no. 4, n (%) 37 (14) 37 (40) 0 (0)  
Item no. 3     
Answer no. 1, n (%) 128 (48) 21 (23) 107 (61) <0.001 
Answer no. 2, n (%) 78 (29) 25 (27) 53 (30)  
Answer no. 3, n (%) 25 (9) 15 (16) 10 (6)  
Answer no. 4, n (%) 37 (14) 32 (34) 5 (3)  
Item no. 4     
Answer no. 1, n (%) 139 (52) 24 (26) 115 (66) <0.001 
Answer no. 2, n (%) 65 (24) 20 (22) 45 (26)  
Answer no. 3, n (%) 27 (10) 21 (23) 6 (3)  
Answer no. 4, n (%) 37 (14) 28 (30) 9 (5)  
Item no. 5     
Answer no. 1, n (%) 117 (44) 13 (14) 104 (59) <0.001 
Answer no. 2, n (%) 86 (32) 31 (33) 55 (31)  
Answer no. 3, n (%) 30 (11) 19 (20) 11 (6)  
Answer no. 4, n (%) 35 (13) 30 (32) 5 (3)  
HA high adherers, LA low adherers, IQR interquartile range. 
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Table 3. Factor analysis 
 
 Loadings 
 All
† HA 
Item no. 1 0.721 0.460 
Item no. 2 0.629 0.522 
Item no. 3 0.750 0.522 
Item no. 4 0.660 0.675 
Item no. 5 0.534 0.807 
 Factor 1 Factor 2 
Sum of square loadings 2.210 1.869 
Proportion Variance 0.442 0.374 
Cumulative Variance 0.442 0.816 
   
 
  
Table 4. Item-fit statistics. 
 
 
Chi-
square df p value 
Outfit 
mean 
square 
Infit 
mean 
square 
Outfit t Infit t 
Item no. 1 224.213 183 0.020 1.219 1.111 1.96 1.05 
Item no. 2 205.899 183 0.118 1.119 1.132 1.17 1.29 
Item no. 3 142.900 183 0.987 0.777 0.740 -2.18 -2.65 
Item no. 4 95.060 183 1.000 0.517 0.523 -4.90 -5.34 
Item no. 5 131.885 183 0.998 0.7171 0.682 -3.05 -3.45 
df degreees of freedom.    
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Table 5. Demographics and clinical variables according to high and low adherence to 
treatment defined by I-CQR5. 
 
  Total HA LA p value 
No. 310 109 201 - 
Females (%) 232 (82) 88 (85.4) 144 (80) 0.081‡ 
Age, years, median (IQR) 57 (48-67) 54 (46-64.8) 59 (49-66) 0.011‡ 
BMI, median (IQR) 24 (22-28) 25 (23-28) 24 (21-27.3) 0.094‡ 
Smokers, n (%) 45 (17.2) 13 (16) 32 (17.7) 0.746 
Employed, n (%) 127 (44.1) 58 (62.4) 69 (35.4) p<0.001‡ 
Education level    0.114 
Primary school, n (%) 35 (12.1) 10 (9.4) 25 (13.6)  
Middle school, n (%) 115 (39.7) 35 (33) 80 (43.5)  
Secondary school, n (%) 101 (34.8) 45 (42.5) 56 (30.4)  
University, n (%) 39 (13.4) 16 (15.1) 23 (12.5)  
Primary/middle school education, n (%)  150 (51.7) 45 (30) 105 (70) 0.016‡ 
Social status    0.921 
Living with parents and family 18 (7) 6 (7.5) 12 (6.8)  
Living alone 34 (13.2) 10 (12.5) 24 (13.6)  
Living with partner and family 187 (72.8) 57 (71.3) 130 (73.4)  
Other 18 (7) 7 (8.8) 11 (6.2)  
Positive RF and/or ACPA, n (%) 129 (43.7) 40 (38.5) 89 (46.6) 0.178 
Disease duration, years, median (IQR) 12 (7-19) 12 (7.3-18) 11 (6.8-20) 0.876 
Fibromyalgia, n (%) 51 (18) 15 (14.6) 36 (20) 0.252 
csDMARD treatment, n (%) 165 (54.5) 44 (40.7) 121 (62.1) p<0.001‡ 
Methotrexate, n (%) 114 (37.6) 32 (29.6) 82 (42.1) 0.033 
Leflunomide, n (%) 31 (10.2) 8 (7.4) 23 (11.8) 0.227 
Other csDMARD, n (%) 42 (13.9) 7 (6.5) 35 (17.9) 0.006 
bDMARD treatment, n (%) 193 (64.3) 79 (76.7) 114 (57.9) 0.001‡ 
Treatment duration>24 months, n (%) 178 (79.5) 75 (78.1) 103 (80.5) 0.667 
PDN daily dose, median (IQR) 1 (0-5) 1 (0-2.5) 1.5 (0-5) 0.011‡ 
NSAIDs, n (%) 185 (65.6) 62 (62.6) 123 (67.2) 0.439 
Painkillers, n (%) 76 (28.6) 30 (30.6) 46 (27.4) 0.574 
Concomitant chronic treatment, n (%) 156 (53.1) 51 (49) 105 (55.3) 0.307 
DAS28, median (IQR) 2.3 (1.8-2.8) 2.1 (1.7-2.7) 2.3 (1.9-2.3) 0.088
‡ 
Remission†, n (%) 173 (57.9) 60 (55.6) 113 (59.2) 0.544 
Low disease activity¥, n (%) 270 (90.3) 101 (93.5) 169 (88.5) 0.158 
Patient - VAS, median (IQR) 30 (10-51) 20 (6-54) 40 (20-56.3) 0.003‡ 
Physician - VAS, median (IQR) 10 (5-20) 12.5 (1.3-20) 10 (5-20) 0.984 
HAQ, median (IQR) 0.5 (0-1) 0.3 (0-1) 0.5 (0.1-1) 0.114 
Disease flares, median (IQR) 44 (31.4) 10 (27) 34 (33) 0.501 
No. of assessments per year, median (IQR) 3 (2-4) 3 (2-4) 3 (2-4) 0.49 
Distance from clinic, km, median (IQR) 30 (11-45) 30 (20-50) 25 (9-45) 0.037‡ 
†defined as DAS28<2.6; ¥defined as DAS28<3.2; ‡variables included in the multivariate analysis as 
achieving a p value <0.10 in the univariate analysis.  
HA high adherers, LA low adherers, IQR interquartile range, BMI body mass index, ACPA anti-citrullinated 
peptides, RF rheumatoid factor, csDMARD conventional synthetic DMARD, bDMARD biological DMARD, 
DMARD disease-modifying anti-rheumatic drug, PDN prednisone, NSAIDs non-steroideal antinflammatory 
drugs, HAQ Health Assessment Questionnaire, DAS28 disease activity score in 28 joints, VAS visual 
analogic scale.  
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Table 6. Demographics and clinical variables according to high and low adherence to 
treatment defined by I-CQR5 and in the patients treated with csDMARDs only or with 
bDMARD. 
 
 csDMARD treatment bDMARD treatment 
 
All HA LA p value All HA LA 
p 
value 
No. 107 24 (22.4) 83 (77.6)  193 79 (40.9) 114 (59.1)  
HA, n (%)* 24 (22.4) - - - 79 (40.9) - - - 
Females (%) 72 (72) 18 (75) 54 (71.1) 0.707 142 (73.4) 52 (65.8) 90 (80.4) 0.024¶ 
Age, years, median (IQR)* 62 (51-70.8) 53.5 (48.5-65) 64.5 (52.5-71) 0.082
‡ 57 (46-65) 54.5 (39.8-28) 57.5 (47-66.3) 0.491 
BMI, median (IQR) 24 (23-28) 24 (23-28) 24 (23-27.5) 0.801 24 (22-28) 25 (23-28) 24 (21-27.8) 0.545 
Smokers, n (%) 17 (18.1) 1 (5.6) 16 (21.1) 0.125 28 (17.6) 12 (21.1) 16 (15.7) 0.394 
Employed, n (%) 42 (39.6) 14 (60.9) 28 (33.7) 0.019‡ 81 (47.1) 41 (64.1) 40 (37) 0.001¶ 
Education level    0.250    0.147 
Primary school, n (%) 14 (14.3) 1 (4.5) 13 (17.1)  20 (11) 8 (10.3) 12 (11.5)  
Middle school, n (%) 45 (45.9) 11 (50) 34 (44.7)  65 (35.7) 21 (26.9) 44 (42.3)  
Secondary school, n (%) 29 (29.6) 9 (40.9) 20 (26.3)  68 (37.4) 34 (43.6) 34 (32.7)  
University, n (%) 10 (10.2) 1 (4.5) 9 (11.8)  29 (15.9) 15 (19.2) 14 (13.5)  
Primary/middle school education, n (%) 
** 59 (60.2) 12 (54.5) 47 (61.8) 0.538 85 (46.7) 29 (37.2) 56 (53.8) 0.026
¶ 
Social status    0.634    0.567 
Living with parents and family, n (%) 3 (3.1) 0 (0) 3 (3.8)  13 (8.7) 5 (9.3) 8 (8.3)  
Living alone, n (%) 16 (16.3) 2 (10) 14 (17.9)  16 (10.7) 6 (11.1) 10 (10.4)  
Living with partner and family, n (%) 69 (70.4) 16 (80) 53 (67.9)  113 (75.3) 38 (70.4) 75 (78.1)  
Other, n (%) 10 (10.2) 2 (10) 8 (10.3)  6 (4) 4 (7.4) 2 (2.1)  
Positive RF and/or ACPA, n (%) 44 (44.4) 9 (45) 35 (44.3) 0.955 79 (42.2) 27 (34.6) 52 (47.7) 0.074¶ 
Disease duration, years, median (IQR)* 8 (4-15) 6 (4-13.8) 8 (4-17) 0.409 15 (9-21) 14 (10-21) 15 (9-21.5) 0.762 
Fibromyalgia, n (%) 13 (14.1) 3 (14.3) 10 (14.1) 0.981 38 (20.8) 12 (15.6) 26 (24.5) 0.141 
csDMARD treatment, n (%)* 107 (100) 24 (100) 83 (100) - 57 (30.5) 19 (24.4) 38 (34.9) 0.124 
Methotrexate, n (%)* 73 (68.2) 16 (66.7) 57 (68.7) 0.852 41 (21.9) 16 (20.5) 25 (22.9) 0.693 
Leflunomide, n (%)* 19 (17.8) 5 (20.8) 14 (16.9) 0.654 12 (6.4) 3 (3.8) 9 (8.3) 0.225 
Other csDMARD, n (%)* 34 (31.8) 6 (25) 28 (33.7) 0.418 7 (3.7) 0 (0) 7 (6.4) 0.023 
bDMARD treatment, n (%) - - - - 193 (100) 79 (100) 114 (100) - 
Type of bDMARD  - - -    0.541 
Abatacept, n (%) - - - - 13 (6.7) 8 (7) 5 (6.3)  
Adalimumab, n (%) - - - - 35 (18.1) 19 (16.7) 16 (20.3)  
Anakinra, n (%) - - - - 11 (5.7) 7 (6.1) 4 (5.1)  
Certolizumab pegol, n (%) - - - - 15 (7.8) 9 (7.9) 6 (7.6)  
Etanercept, n (%) - - - - 101 (52.3) 62 (54.4) 39 (49.4)  
Golimumab, n (%) - - - - 8 (4.1) 6 (5.3) 2 (2.5)  
Tocilizumab, n (%) - - - - 10 (5.2) 3 (2.6) 7 (8.9)  
bDMARD administration every ≤ 1 
week, n (%) - - - - 110 (57) 43 (54.4) 67 (58.8) 0.549 
Low-dose of the bDMARD, n (%) - - - - 82 (42.7) 29 (49.4) 43 (37.7) 0.091¶ 
Previous bDMARD failures, n (%) - - - - 62 (38.5) 29 (38.7) 33 (38.4) 0.969 
Duration of bDMARD treatment, 
months, median (IQR) - - -  88 (45-61.8) 88 (47-130) 
86 (41.5-
120)** 0.992 
Combination treatment, n (%)** 19 (17.8) 3 (12.5) 16 (19.3) 0.444 57 (30.5) 19 (24.4) 38 (34.9) 0.124 
Treatment duration>24 months, n (%)* 27 (65.9) 11 (68.8) 16 (64) 0.754 149 (83.7) 63 (82.9) 86 (84.3) 0.8 
PDN daily dose, median (IQR)* 1 (1-5) 1 (1-2.5) 1 (1-5) 0.211 1.5 (0-5) 0 (0-5) 2.5 (0-5) 0.13 
NSAIDs, n (%) 68 (64.8) 12 (52.2) 56 (68.3) 0.153 111 (66.1) 47 (67.1) 64 (65.3) 0.804 
Painkillers, n (%) 21 (21.4) 4 (17.4) 17 (22.7) 0.59 50 (31.4) 22 (31.9) 28 (31.1) 0.917 
Concomitant chronic treatment, n (%)* 59 (58.4) 10 (43.5) 49 (62.8) 0.098 91 (49.7) 38 (50.7) 53 (49.1) 0.832 
         
DAS28, median (IQR) 2.2 (2-2.8) 2.1 (2-2.5) 2.3 (2-2.8) 0.57 2.3 (1.8-2.8) 2.3 (1.7-2.8) 2.4 (1.8-3.0) 0.441 
Remission†, n (%) 64 (64) 16 (66.7) 48 (63.2) 0.755 101 (52.9) 39 (49.4) 62 (55.4) 0.414 
Low disease activity¥, n (%) 88 (88) 23 (95.8) 65 (85.5) 0.176 174 (91.1) 73 (92.4) 101 (90.2) 0.595 
Patient - VAS, median (IQR) 26.5 (10-48.5) 10 (0-35) 30 (10-50) 0.03
‡ 38 (20-66) 30 (10-50) 45 (28-69) 0.03¶ 
Physician - VAS, median (IQR) 10 (5-20) 10 (0-20) 10 (5-20) 0.876 10 (5-15) 10 (0-15) 10 (5-20) 0.988 
HAQ, median (IQR)* 0.1 (0-0.6) 0.1 (0-0.5) 0.3 (0-0.6) 0.276 0.6 (0.1-1.1) 0.5 (0-1.1) 0.8 (0.3-1.1) 0.14 
Disease flares, median (IQR) 33 (37.1) 5 (31.3) 28 (38.4) 0.594 11 (26.2) 5 (33.3) 6 (22.2) 0.433 
No. of assessments per year, median 
(IQR)* 2 (2-2) 2 (2-2) 2 (2-3) 0.104 4 (3-4) 4 (3-4) 4 (3-4) 0.98 
Distance from clinic, km, median (IQR)* 18 (4-30) 22.5 (15-56.5) 15 (3-30) 0.044
‡ 32 (18-50) 30 (20-50) 35 (18-50) 0.948 
†defined as DAS28<2.6; ¥defined as DAS28<3.2; ‡variables included in the multivariate analysis in patients treated with csDMARDs only, as achieving a p 
<0.1; ¶ variables included in the multivariate analysis in patients treated with bDMARDs as achieving a p <0.10; *significant difference observed in the cohort 
between patients treated with bDMARDs and those with synthertic DMARDs only with p<0.01 and ** p<0.05. 
csDMARD conventional synthetic DMARD, bDMARD biological DMARD, DMARD disease-modifying anti-rheumatic drug, HA high adherers, LA low 
adherers, IQR interquartile range, BMI body mass index, ACPA anti-citrullinated peptides, RF rheumatoid factor, PDN prednisone, NSAIDs non-steroideal 
antinflammatory drugs, HAQ Health Assessment Questionnaire, DAS28 disease activity score in 28 joints, VAS visual analogic scale. 
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Table 7. Factors associated with high adherence to anti-rheumatic treatment 
defined by I-CQR5: a multivariate regression analysis model.  
 
 OR (95% C.I.) p value 
Female gender 0.79 (1.58-0.39) 0.501 
Employment 2.36 (1.21-4.62) 0.012 
bDMARD treatment 2.88 (1.36-6.1) 0.006 
Patient-VAS (per 10-unit increase) 0.88 (0.78-1) 0.052 
Model constant  <0.001 
OR odds ratio, C.I. confidence interval, bDMARD biological DMARD, DMARD disease-modifying 
anti-rheumatic drug, VAS visual analogic scale. 
 
 
 
Table 8. Factors associated with high adherence to anti-rheumatic treatment defined by 
I-CQR5, two separate multivariate regression models for patients treated csDMARDs only 
and with bDMARDs.  
 
 csDMARD treatment bDMARD treatment 
 OR (95% C.I.) p value OR (95% C.I.) p value 
Female gender   2.05 (0.9-4.66) 0.086 
Employment 1.95 (0.56-6.83) 0.296 2.89 (1.3-6.44) 0.009 
Patient-VAS (per 10-unit 
increase)  0.77 (0.55-1.06) 0.105 0.95 (0.83-1.09) 0.453 
Distance from clinic, km 
(per 10-unit increase) 1.13 (0.89-1.44) 0.31   
Model constant  0.025  0.035 
OR odds ratio, C.I. confidence interval, csDMARD conventional synthetic DMARD, bDMARD biological 
DMARD, DMARD disease-modifying anti-rheumatic drug, VAS visual analogic scale. 
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Figure 1. Schematic enrolment of the patients in the study. 
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Figure 2. Final I-CQR5 version. 
 
 
 
